ProLonged Liposomal Delivery of TLR7/8 Agonist for Enhanced Cancer Vaccine

Area of Science:

• Immunology
• Oncology
• Nanotechnology

Background:

• Cancer remains a significant global health challenge despite extensive research.
• Cancer vaccines show promise but face efficacy limitations.
• Toll-like receptor (TLR) adjuvants, particularly TLR 7/8 agonists, can enhance immune responses against cancer.

Purpose of the Study:

• To develop and evaluate ProLNG-001, a novel liposomal formulation of a TLR 7/8 agonist (resiquimod), for improved cancer vaccine efficacy.
• To assess the ability of ProLNG-001 to enhance systemic anti-tumor immunity and T cell activation.
• To compare the efficacy of ProLNG-001 with existing adjuvant systems in a preclinical cancer model.

Main Methods:

• Development of ProLNG-S, a cholesterol-conjugated resiquimod, formulated into ProLNG-001, a positively charged liposome.
• Co-administration of ProLNG-001 with ovalbumin (OVA) antigen in the B16-OVA mouse model.
• Evaluation of immune cell targeting, systemic immune response, and anti-tumor efficacy.

Main Results:

• ProLNG-001 effectively targeted secondary lymphoid organs.
• ProLNG-001 induced a robust systemic anti-tumor immune response and tumor-specific T cell activation.
• ProLNG-001 demonstrated superior potential in preventing tumor progression and improving survival compared to the AS01 adjuvant.

Conclusions:

• ProLNG-001 represents a promising advancement in cancer vaccine adjuvants.
• The novel liposomal formulation enhances anti-tumor immunity by stimulating the immune system.
• ProLNG-001 holds potential for improving cancer treatment strategies by overcoming current vaccine efficacy limitations.